Skip to content
Veracyte® Press Releases

Veracyte® Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Third Quarter 2022 Financial Results
Grew Total Revenue to $75.6 million , an Increase of 25% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2022 .
View HTML
Toggle Summary Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting
- New findings reinforce potential of company’s multi-omics capabilities and tools in immuno-oncology to address biopharma partners’ unique oncology drug development needs - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 1, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that three
View HTML
Toggle Summary Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 27, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in a fireside chat at the Credit Suisse 31 st Annual Healthcare Conference on
View HTML
Toggle Summary New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy
Findings shared in an oral presentation at ASTRO Annual Meeting 2022 suggest predictive biomarker could help guide treatment in men experiencing disease progression after surgery SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 25, 2022-- Veracyte, Inc .
View HTML
Toggle Summary Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer
Findings Derived from Company’s Extensive Thyroid Nodule Database and Whole-Transcriptome Capabilities SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 24, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced data that provide new insights into thyroid tumor behavior.
View HTML
Toggle Summary New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 18, 2022-- Veracyte, Inc . (Nasdaq: VCYT) today announced that two abstracts highlighting the clinical value of the company’s Envisia Genomic Classifier and Percepta Nasal Swab tests in interstitial lung disease (ILD) and lung cancer,
View HTML
Toggle Summary Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 13, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the third quarter of 2022 after the close of market on Wednesday, November 2, 2022 . Company management will host a conference call and webcast to
View HTML
Toggle Summary New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 22, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced that data published today in the Journal of the National Cancer Institute demonstrate that the company’s Decipher Prostate Genomic Classifier may help identify African American men with early,
View HTML
Toggle Summary Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 13, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that John Leite , Ph.D., has joined the company as senior vice president and general manager of Pulmonology & Market Access. Dr. Leite’s responsibilities will include leading commercial
View HTML
Toggle Summary New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
Findings from ancillary study of Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes in men with high-risk non-metastatic and metastatic prostate cancer Data support Veracyte’s plan to expand test availability in the U.S.
View HTML